Abstract We examined the association of TIMP-1 and TIMP-2 gene polymorphisms with the progression of chronic liver disease related to the hepatitis C virus (HCV). We used PCR to analyze 188 patients with HCV-related liver disease (95 with chronic hepatitis and 93 with cirrhosis) for TIMP-1 372 T/C and TIMP-2 -418 G/C polymorphisms. Comparing chronic hepatitis and cirrhosis, there were no significant differences in TIMP-1 and TIMP-2 gene polymorphisms. Among chronic hepatitis patients, TIMP-2 -418 G homozygotes showed significantly faster fibrosis progression than C carriers. Among cirrhotic patients, males with the TIMP-1 372 T allele developed cirrhosis at a younger age, and patients who were homozygous for the higher-transcription TIMP-2 -418 G allele had significantly lower serum albumin concentrations. These results suggest that faster progression of liver fibrosis could be associated with TIMP-2 -418 G homozygotes.
Introduction
Chronic liver disease related to the hepatitis C virus (HCV) is one of the most important health issues worldwide. Approximately 170 million people, or 3% of the world population, are chronically infected with HCV (Marcellin 2009 ). Chronic HCV infection commonly induces reactive immune inflammation, which results in continuous liver tissue damage and progression of liver fibrosis to cirrhosis. Liver fibrosis is a highly dynamic process, and the rate at which fibrosis develops shows substantial individual variation. A previous report showed that some individual features, such as male gender, older age at infection, excessive alcohol consumption, overweight, and immunodeficiency, are significantly associated with liver fibrosis progression (Marcellin et al. 2002) . The factors that promote and protect against HCV-related liver fibrosis, however, remain poorly understood.
Numerous functional gene polymorphisms related to extracellular matrix metabolism (ECM) have been identified, and some reports have shown possible relationships between these genotypes and progression of fibrosis in chronic liver disease (Promrat et al. 2003) . Cytokines, growth factors, proteinases, and their inhibitors play essential roles in regulating ECM remodeling. Matrix metalloproteinases (MMPs) are involved in the degradation of numerous ECM components (Polette and Birembaut 1998) . The biological activity of MMPs is tightly regulated by specific inhibitors known as tissue inhibitors of matrix metalloproteinases (TIMPs).
TIMPs are thought to play important roles in the liver fibrosis process (Friedman 2003; Hemmann et al. 2007) . TIMPs stoichiometrically interact with MMPs to inhibit their activity (Arthur 2000) . Four TIMP isoforms (TIMP-1, -2, -3, and -4) have been identified to date (Baker et al. 2002) . In hepatic tissue, those primarily expressed are TIMP-1 and TIMP-2 (Nie et al. 2010) . In chronic liver disease, significant increases in TIMP-1 and TIMP-2 expression have also been observed (Murawaki et al. 1997 (Murawaki et al. , 1999 . Although all four TIMPs bind to most MMPs, the inhibitory properties of the TIMPs differ toward each MMP. For example, TIMP-1 preferentially binds and inhibits MMP-1 and MMP-9, and TIMP-2 inhibits MMP-2 activity. These characteristics lead to functional differences among TIMPs (Wei et al. 2003) . Several functional single nucleotide polymorphisms (SNPs) have been described in the genes encoding TIMPs (Krex et al. 2003; Meijer et al. 2007; De Clerck et al. 1994; Hirano et al. 2001; Faisst and Meyer 1992; O-charoenrat and Khantapura 2006) .
The TIMP-1 gene is located on chromosome X (Xp11) and has several polymorphisms. Meijer et al. (2007) showed that the TIMP-1 372 T/C genotype (rs4898) has a positive relationship with susceptibility to chronic bowel inflammatory disease and that men with the T allele had lower TIMP-1 protein expression in inflamed tissue.
TIMP-2 is known as a strong regulator of MMP-2 activity. The TIMP-2 gene is located at 17q25, and a single nucleotide G/C polymorphism has been identified at position -418 in the promoter region (rs8179090) (De Clerck et al. 1994; Hirano et al. 2001) . The presence of the G allele is associated with increased TIMP-2 expression, possibly because the G allele favors binding of the Sp1 transcription factor (Faisst and Meyer 1992; O-charoenrat and Khantapura 2006) .
The TIMP-1 and TIMP-2 polymorphisms appear to be favorable genetic factors for predicting the speed of the progression of chronic liver disease. In this study, we investigated the possible association of TIMP-1 and TIMP-2 polymorphisms with the progression of liver fibrosis in Japanese patients with HCV-related chronic liver disease.
Materials and Methods

Subjects
All study subjects with chronic HCV infection were recruited from the ambulatory patients of Tottori University Hospital. Overall, 188 patients with HCV-related chronic liver disease, either chronic hepatitis or liver cirrhosis, were enrolled in this study (Table 1 ). All patients were Japanese and were positive for serum HCV-RNA. Patients were excluded if they had chronic hepatitis B infection, alcoholism (or habitually drank more than 150 g ethanol per day), autoimmune hepatitis, or primary biliary cirrhosis. Diagnosis of chronic hepatitis and liver cirrhosis was confirmed by histological examinations and/or clinical features, laboratory tests, and imaging tests (computer tomography and magnetic resonance imaging). All patients enrolled in the study were given routine blood liver function tests every 3 months at the Department of Multidisciplinary Internal Medicine, Tottori University School of Medicine. The liver function of 50 of the chronic hepatitis patients was tracked in this way over the course of 5 years. This study was approved by the Committee for the Ethics of Medical Experiments on Human Subjects of the Medical Faculty of Tottori University, and written informed consent was obtained from each subject before blood was collected.
DNA Extraction
Genomic DNA was extracted from peripheral white blood cells using a DNA extraction kit (DNA Quick II, Dainippon Pharmaceutical, Osaka, Japan) according to the manufacturer's instructions. The TIMP-1 372 T/C polymorphism was analyzed by the Cycleave PCR technique (Takara, Shiga, Japan), using a DNA/RNA chimeric probe-adapted real-time PCR (Bekkaoui et al. 1996; Duck et al. 1990 ). Sequences of the primer set and probes were as follows: PCR forward primer, 5 0 -AAACTGCAGGATGGACTCTT-3 0 ; PCR reverse primer, 5 0 -GAAACAAGCCCACGATTTAG-3 0 ; T allele probe, 5 0 Eclipse-AGCCACAAAA-FAM-3 0 ; C allele probe, 5 0 Eclipse-GCCACGAAA-FAM-3 0 (italics represent RNA). The PCR conditions were 95°C for 25 s, followed by 45 cycles of denaturation at 95°C for 5 s, primer annealing at 55°C for 10 s, and extension and fluorescence emission at 72°C for 15 s. Fluorescent signals were assessed using a LightCycler 1.5 (Roche, Mannheim, Germany).
Analysis of the TIMP-2 -418 G/C Polymorphism
The TIMP-2 -418 G/C polymorphism was analyzed by PCR, followed by restriction fragment length polymorphism (RFLP) analysis, as described previously (Zhou et al. 2004) . PCR was carried out in a final volume of 50:2 lL (5 ng) genomic DNA, 0.2 lL of 20 nM forward primer (5 0 -CGTCTCTTGTTGGCTGGTCA-3 0 ) and of 20 nM reverse primer (5 0 -CCTTCAGCTCGACTCTGGAG-3 0 ), 2.0 lL dNTPs, 0.2 lL Taq polymerase (Takara, Shiga, Japan), 2.5 lL 109 PCR buffer, and 18 lL sterile H 2 O. Conditions for amplification were 94°C for 2 min; 35 cycles of 94°C for 30 s, 59°C for 30 s, and 72°C for 1 min; and 72°C for 7 min. RFLP for TIMP-2 -418 G/C was then performed. A mixture of 8 lL PCR product, 5 lL 109 NE buffer 2, 0.5 lL BsoBI (New England BioLabs, Beverly, MA), and 36.5 lL sterile H 2 O was incubated at 37°C overnight. The mixture was loaded onto a polyacrylamide gel (total concentration 10%; concentration of cross-linker 3%; 19 TBE buffer: 89 mM Tris, 89 mM borate, and 2.2 mM EDTA). Electrophoresis was performed at 200 V for 70 min at 20°C using 19 TBE buffer; the G allele gives three bands (230, 51, and 23 bp) , and the C allele gives two bands (253 and 51 bp). Bands were visualized by silver staining.
Analysis of Liver Fibrosis Progression
We followed 50 of the 95 chronic hepatitis patients for 5 years with blood tests. We then divided the 50 chronic hepatitis patients into two groups (a progressive fibrosis group and an unchanged group), based on changes in the Forns index (Forns et al. 2002) and the FibroIndex (Koda et al. 2007 ) during the 5-year period, and then compared the TIMP-1 372 and TIMP-2 -418 genotypes of these groups. (For the FibroIndex calculations, n = 49 because one person did not have c-globulin data.) Progressive cases showed an index change greater than zero after 5 years; the unchanged cases showed an index change less than or equal to zero.
The Forns index was calculated as 7.811 -3.131 ln (platelet count) ? 0.781 ln (GGT) ? 3.467 ln (age) -0.014 (cholesterol). The FibroIndex was 1.738 -0.064 (platelet count 9 10 4 /mm 3 ) ? 0.005 (AST IU/L) ? 0.463 (c-globulin g/dL).
Statistical Analysis
Values are expressed as means plus or minus standard deviation. Differences in genotype distributions were determined with the chi-square test. Differences in data for the two subject groups were assessed using Student's t test, the chi-square test, and Fisher's exact test where appropriate. A p value of less than 0.05 was regarded as statistically significant.
Results
The TIMP-2 and female TIMP-1 genotypes were distributed in accordance with the Hardy-Weinberg equation (p = 0.569 and 0.845, respectively). TIMP distributions in our HCV-positive patients were similar to those reported previously in healthy Japanese populations (Hirano et al. 2001) . We found no significant differences between patients with chronic hepatitis and those with liver cirrhosis in genotype and allele frequencies of TIMP-1 372 T/C and TIMP-2 -418 G/C (Table 2) . TIMP-1 372 T/C genotypes affected neither index differences nor genotype distributions between the progressive group and the unchanged group (Table 3) . The difference over the course of 5 years was significantly higher for TIMP-2 -418 G homozygotes than for C carriers on both the Forns index (p = 0.03) and the FibroIndex (p = 0.04). Chronic hepatitis patient classification based on changes in fibrosis index values over the 5-year period also suggested that TIMP-2 -418 G homozygotes were more common in the progressive group than were C carriers (p = 0.03 for the FiboroIndex) (Table 4) .
To examine the effects of TIMP-1 and TIMP-2 genotypes on patients with advanced liver fibrosis, we compared clinical liver function parameters in liver cirrhosis patients. With regard to TIMP-1 372 T/C, no clinical features showed a significant difference in females. In males, the TIMP-1 372 T allele was significantly related to liver cirrhosis diagnosis at a younger age (Table 5) . Serum albumin was significantly lower in patients who were homozygous for the highertranscription TIMP-2 -418 G allele (De Clerck et al. 1994 ) than in -418 C carriers (p = 0.007). Indocyanine green retention at 15 min and Child-Pugh scores were somewhat higher in -418 G homozygotes than in C carriers (p = 0.052 and 0.059, respectively) ( Table 5 ).
Discussion
In this study, we examined the association of TIMP-1 372 T/C and TIMP-2 -418 G/C polymorphisms with the progression of fibrosis in Japanese patients with chronic liver disease. We found that the disease progressed significantly faster in patients who were homozygous for the higher-transcription TIMP-2 -418 G allele.
The TIMP-1 gene is located at Xp11.3-p11.23, and three polymorphisms have been identified (Krex et al. 2003) : TIMP-1 19 C/T in the 5 0 -UTR; TIMP-1 261 C/T in exon 4; and TIMP-1 372 T/C in exon 5. The TIMP-1 372 T/C polymorphism accounts for most polymorphisms in the gene; the frequency of polymorphisms at the other two sites is very low (Hinterseher et al. 2007 ). To the best of our knowledge, there are no previous studies on associations between the TIMP-1 polymorphism and liver fibrosis progression, although several studies have examined the relationship between the TIMP-1 372 T/C polymorphism and chronic inflammatory diseases. The TIMP-1 372 T/C polymorphism has no effect on amino acid sequence (F124F). The T allele, however, is associated with lower TIMP-1 protein expression; Meijer et al. (2007) showed that male patients with inflammatory bowel disease who carry the TIMP-1 372 T allele express lower levels of TIMP-1 in surgically resected inflamed tissue than do C allele carriers. Indelicato et al. (2006) observed that the TIMP-1 372 C allele frequency was higher in male patients with systemic sclerosis than in healthy individuals, and Wei et al. (2009) reported that carriers of the TIMP-1 372 C allele had a greater risk of developing ankylosing spondylitis. In males, carriers of the TIMP-1 372 T allele were diagnosed with liver cirrhosis at a younger age than were C allele carriers. For patients with an advanced stage of liver fibrosis, the TIMP-1 372 T allele seemed to be a risk factor for disease progression. In female patients, no significant differences were seen. The reason is unknown, but it is hypothesized that the gender difference may be due to the TIMP-1 gene's location at Xp11.3-p11.23. Males have only one X chromosome, and the functional difference of the TIMP-1 372 gene polymorphism emerges more clearly because no heterozygotes are formed. TIMP-2 also plays a regulatory role in the proteolytic activation of MMPs. The SNP -418 G/C in the promoter region of the TIMP-2 gene affects transcription (Hirano et al. 2001 ). This G?C substitution, located within the consensus sequence for the Sp1 binding site (GAGGCTGGG) in the promoter region, may downregulate transcriptional activity and lead to an imbalance between the activities of TIMP-2 and MMP-2 (O-charoenrat and Khantapura 2006). Gene expression is lower when the less common C allele is present. Several epidemiological studies have investigated the association between TIMP-2 polymorphism and various diseases such as chronic inflammation, chronic obstructive pulmonary disease (Hirano et al. 2001; Hegab et al. 2005) , aneurysm (Krex et al. 2003) , and adenomyosis (Kang et al. 2008 ). To our knowledge, no previous study has demonstrated the relationship between the TIMP-2 -418 gene polymorphism and HCV-related chronic liver Table 3 . Index difference is expressed as mean ± SD * Statistically significant at p \ 0.05 Table 5 Clinical findings for liver cirrhosis patients, by TIMP-2 disease. We used two indexes to analyze the progression of fibrosis and found that among chronic hepatitis patients the greater level of transcription in TIMP-2 -418 G homozygotes is related to more rapid fibrosis progression than that seen in C carriers. TIMP-2, as the main inhibitor of MMP-2, plays a unique role in regulating MMP-2 activity. The affinity of TIMP-2 for MMP-2, which is 10 times that of TIMP-1, strongly inhibits TIMP-2 activation (Yi et al. 2009 ). MMP-2 plays an important role in the degradation of collagen IV. Nie et al. (2010) reported that increased expression of TIMP-2 causes a decrease in MMP-2 activity, resulting in deposition of collagen IV in immune-induced liver fibrosis in animal models. On the other hand, the latent form of MMP-2 (pro-MMP-2) is activated on the cell surface by membrane type 1 (MT1)-MMP (also known as MMP-14) and TIMP-2. A complex of active MT1-MMP and TIMP-2 binds pro-MMP-2 and forms a ternary complex, which permits pro-MMP-2 activation via a TIMP-2-free neighboring MT1-MMP (Bernardo and Fridman 2003) . A TIMP-2 functional balance between activation and inhibition of MMP-2 apparently tends toward suppressing effects in chronic liver disease.
This study has some limitations. Our sample size was relatively small, the statistical power was poor, and some potential biases may be present, such as the selection of patients who could take medical tests regularly at our university hospital. In addition, five years is too short a period for measuring significant differences in liver fibrosis progression. In patients with HCV-related chronic hepatitis, the median rate of fibrosis progression per year is about 0.1 Metavir unit (Poynard et al. 1997) . Future studies would be strengthened by increasing the sample size, as well as by following the patients longer.
In conclusion, we demonstrated that TIMP-1 372 T/C and TIMP-2 -418 G/C gene polymorphisms influence fibrosis progression in HCV-related chronic liver disease. Patients with the higher-transcription TIMP-2 -418 G allele showed accelerated liver fibrosis progression. Further studies using a larger sample size of Japanese patients with HCV-related chronic liver disease are required to confirm the association between TIMP-2 polymorphism and the progression of liver fibrosis.
